Salus BioMed, founded in 2020 in Shenzhen, China, is a leading provider of genomics and spatial omics solutions. The company specializes in developing advanced DNA sequencing platforms and high-definition spatial transcriptomics technologies to measure gene activity, aiding in the diagnosis and treatment of diseases. Their product lineup includes the Saluseq Nimbo, Salus Pro, and Salus EVO sequencing platforms, as well as ST Chip and Reagent Kits for spatial transcriptomics applications. In February 2025, Salus Pro received Chinese NMPA regulatory approval, marking a significant milestone for the company and the precision diagnostics industry.

WEBSITE 
BROCHURE